Assembly Biosciences
ASMB· Manufacturing· Fiscal year ends in December
Jason A. Okazaki is the CEO of Assembly Biosciences and was paid $2.5M in FY2025 (Dec), up 41%.
Executives3
See all- 1Jason A. OkazakiChief Executive Officer and PresidentFY2025
- 2William E. Delaney IV, Ph.D.Chief Scientific OfficerFY2025
- 3Anuj Gaggar, M.D., Ph.D.Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAssembly Biosciences paid its 3 named executives $5.0M in total in FY2025 (Dec). CEO Jason A. Okazaki was paid $2.5M of that.
| Name | |||
|---|---|---|---|
| Jason A. OkazakiChief Executive Officer and President | |||
| William E. Delaney IV, Ph.D.Chief Scientific Officer | |||
| Anuj Gaggar, M.D., Ph.D.Chief Medical Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of Assembly Biosciences names 18 peer companies for pay. Among Assembly Biosciences and these peers, CEO pay was 5th highest of 9 and total shareholder return was 2nd highest of 9.
5th highest of 9in Assembly Biosciences and its pay peers, FY2025 (Dec) by CEO pay:
2nd highest of 9in Assembly Biosciences and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board3
See all- Susan Mahony, Ph.D.Director · 7 yr on the boardIndependentCompensation (Chair), Science and Technology—Paid as an executive
- John G. McHutchison, A.O., M.D.Director · 5 yr on the boardNot independentScience and Technology (Chair)—Paid as an executive
- Robert D. Cook IIDirector · 0 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 19, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 17, 2024 | FY2023 |
| Annual report | 10-K | Mar 28, 2024 | FY2023 |
